Future Medicine Co., Ltd.

As of December 31, 2025, Future Medicine Co., Ltd. carries a market capitalization of 32.65B, placing it among publicly traded companies globally. Its enterprise value stands at 35.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Future Medicine Co., Ltd. has 10.53M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Future Medicine Co., Ltd. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -89.51, indicating conservative leverage, while an interest coverage ratio of -9.69 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -114.57, reflecting losses generated across the asset base.

As of the close on October 13, 2026, Future Medicine Co., Ltd.'s stock has declined approximately 98.00% over the past 52 weeks. The 50-day moving average sits at 413.24, while the 200-day moving average is 1,392.30.

These figures cover the twelve months ended December 31, 2025. EBITDA reached -1.39B, while operating income came in at -1.63B.

As of December 31, 2025, Future Medicine Co., Ltd. holds 212.46M in cash and equivalents against 3.17B in total debt, resulting in a net debt position of 2.79B. Total book value stands at -3.54B, with working capital of -3.51B providing operational flexibility.

Future Medicine Co., Ltd. produced -1.18B in operating cash flow over the twelve months ended December 31, 2025.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -3.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.23, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Future Medicine Co., Ltd. shareholders.